Who will compete with multinational pharmaceutical companies in 2019?

As of February 10, the annual reports of the world's large multinational pharmaceutical companies in 2019 have been basically published With the problems of generic drug competition, market price pressure, etc., in 2019, multinational pharmaceutical enterprises ensure the competitiveness and market position of innovative products through investment, M & A of small and medium-sized enterprises with R & D strength, split and sell off of secondary products (lines) and departments, etc it seems that we can see from the financial statements that this trend will continue or will continue in 2020 The following is a brief look at the 2019 performance and development plan of the world's major multinational pharmaceutical companies: Johnson & Johnson's annual sales in 2019 was $82.06 billion, an increase of 0.6% over 2018, R & D expenditure was $11.36 billion, an increase of 5.4% year-on-year, accounting for 13.8% of the annual sales; sales and management expenditure was $22.18 billion, accounting for 27%, a decrease of 1.6% year-on-year Among them, the annual revenue of consumer health care business is 13.9 billion US dollars, up 1.4% year on year, which is driven by Neutrogena beauty products and over-the-counter products such as Tylenol and Motrin analgesics However, infant care products are 1.68 billion US dollars, down 6.1% year on year, partially offset by the decline in sales of infant care products In addition, in 2019, the sales volume of Johnson & Johnson's pharmaceutical business reached US $42.2 billion, mainly driven by the immunodrugs stellara (US $6.36 billion, + 25.2%), tremfya (US $1.01 billion, + 87.7%), cancer treatment drugs darzalex (US $3 billion, + 52.2%), imbruvica (US $3.41 billion, + 34.5%), erlada, antipsychotics invgasustenna / xeplion / invgatrinza / trevicta (US $3.33 billion) ，+15.8%）。 Revenue growth in the pharmaceutical business was partially offset by competition for bio generic and generic drugs, mainly due to a decline in REMICADE's global market (US $4.38 billion, - 16.8%), zytiga's US market (US $810 million, - 54.3%) and Velcade's international market (US $750 million, - 30.1%) Johnson & Johnson's medical equipment business also performed well in 2019, with an annual sales volume of US $25.96 billion, benefiting from electrophysiological products for intervention, energy and endoscope products for surgery, and Acuvue contact lenses for ophthalmology Therefore, we boldly forecast the sales revenue of J & J in 2020 The total revenue in 2020 is expected to be 85.8-86.6 billion US dollars, and the sales and profits will continue to grow According to Roche's financial report in 2019, Roche's sales in 2019 were CHF 61.5 billion, equivalent to about USD 62.88 billion, up 9% year on year In 2019, annual sales of Roche pharmaceutical and pharmaceutical division increased by 11% to 48.5 billion Swiss francs (about 49.59 billion US dollars) The main growth drivers were the multiple sclerosis drug ocrevus (CHF 3.71 billion, + 57%), the new hemophilia drug hemlibra (CHF 1.38 billion, + > 500%), the cancer drug tecentriq (CHF 1.88 billion, + 143%), and perjeta (CHF 3.52 billion, + 29%) Mabthera / rituxan (CHF 6.48 billion, - 4%), Herceptin (CHF 6.04 billion, - 12%) and Avastin (CHF 7.07 billion, + 4%) are facing global bio generic competition, which has a significant impact on us, European and Japanese market revenue However, the number of patients of these three products in China increased significantly, with strong sales, driving the overall sales volume of the pharmaceutical business in the international regions (excluding the United States, Europe and Japan) to increase by 15% In addition, sales in the diagnostics sector increased by 3% to CHF 12.9 billion (US $13.19 billion) Its main businesses are central and point of care solutions, molecular diagnosis, diabetes care and tissue diagnosis Roche expects sales to grow in the low to medium single digit range in 2020 Pfizer's revenue in 2019 was US $51.8 billion, up 1% year on year in 2018; R & D expenditure was US $8.65 billion, up 8% year on year; sales and management expenditure was US $14.35 billion, down 1% year on year The annual revenue of biopharmaceutical business is 39.4 billion US dollars, 8% higher than that in 2018, mainly due to the global growth of cancer treatment drug ibrance (4.96 billion US dollars, + 23%), internal medicine drug eliquis (4.22 billion US dollars, + 26%), inflammatory immunotherapy drug xeljanz (2.24 billion US dollars, + 29%) and rare disease drug vyndaqel / vyndamax (470 million US dollars, + > 200%); vaccine prevenar13 is emerging The expansion of the market (US $1.61 billion, + 21%) and the performance of cancer drug inlyta in the US market (US $300 million, + > 100%) The negative impact is that the sales volume of Enbrel in the international market (US $1.7 billion, - 14%) and prevnar13 in the US market (US $3.21 billion, - 4%) Upjohn (non patent brand and generic pharmaceutical business) has revenue of US $10.2 billion (- 16%), completing the merger with mylan The decline in revenue was mainly due to the loss of patents by Lyrica in the US market (US $2.01 billion, - 44%) and increased generic competition by Viagra in the US (US $80 million, - 65%) However, in China, revenue increased by 7%, and the key products were Viagra (Viagra), Celebrex, Zoloft, Lyrica, which were not affected by VBP, and Lipitor and Norvasc in some provinces were affected by VBP Revenue from the consumer healthcare business fell 40% to $2.1 billion as Pfizer took a 32% stake in GSK's merger into a joint venture In 2020, Pfizer expects total revenue of US $48.5-50.5 billion Upjohn began managing meridian, a maker of Pfizer's Epipen and other automatic syringe products, as well as generics in partnership with mylan Japan "New" Pfizer will be mainly reflected in the elimination of meridian and the biopharmaceutical business after cooperation with mylan In 2019, the annual sales volume of moshadong was 46.8 billion US dollars, up 11% year on year, the R & D expenditure was 9.9 billion US dollars, and the sales and management expenses were 10.6 billion US dollars, up 5% Among them, pharmaceutical business sales reached US $41.75 billion, up 11% year on year Mainly benefited from the sales of $11.9 billion in oncology products and $8.4 billion in vaccine products, including "mainstay" cancer drug keytruda (US $11.08 billion, + 55%), joint development of cancer drug lynparza (US $440 million, + 137%), lenvima (US $400 million, + 171%); and vaccines Gardasil / Gardasil 9 (US $3.74 billion, + 19%) and ProQuad / m-rii / Varivax (22.8 billion) US $billion, + 27%) In addition, the rapid growth of hospital emergency treatment drug bridion (1.1 billion US dollars, + 23%) Due to the loss of market monopoly of some products, the sales revenue of MSD in 2019 is slightly affected Including the emergency medicine noxafil (US $660 million, - 11%), cupicin (US $260 million, - 30%), cancer medicine emend (US $390 million, - 26%), cardiovascular medicine zetia (US $590 million, - 31%), Vytorin (US $290 million, - 43%), immune medicine REMICADE (US $410 million, - 29%); and the continuous price pressure of diabetes medicine, involving januvia (US $3.48 billion, - 6%) And janumet ($2.04 billion, - 8%) Animal health business sales of US $4.4 billion were mainly due to the acquisition of antelliq's livestock products and high sales of companion animal products, such as bravecto, a parasite control product In 2020, MSD will spin off assets such as women's health, patented brand drugs and bio similar drugs and become an independent new company "New" MSD is committed to becoming a research and development intensive biopharmaceutical company, retaining key growth point products such as tumor, vaccine, in hospital products and animal health care, and investing in research and development, pursuing scientific research and innovation It is estimated that the sales volume will be between 48.8-50.3 billion US dollars in 2020 The annual sales of Novartis in 2019 was US $47.45 billion, a year-on-year increase of 9%; R & D expenditure was US $9.4 billion, a year-on-year increase of 10.8%; sales and management expenditure was US $14.37 billion, a year-on-year increase of 4.8% In 2019, annual sales of Novartis' innovative drug business was $37.71 billion (+ 11%), and its core profit margin increased to 33.5% of sales Among them, the sales volume of cancer unit is US $14.37 billion (+ 10%), the key products are lutathera (US $440 million, + 160%), promata / revolve (US $1.42 billion, + 23%), kisquali (US $480 million, + 111%); the sales volume of pharmaceutical unit is US $23.34 billion, + 12%), the key products are immune drug cosentix (US $3.55 billion, + 28%), metabolic disease drug enter rest O (US $1.73 billion, + 71%) and zolgensma (US $361 million, first year) The annual sales volume of the non patent medicine business Sandoz is 9.73 billion US dollars (+ 2%) Despite continued price pressures in the US market, the business resumed sales growth and margin expansion driven by global biopharmaceuticals, thanks to strong double-digit growth in the European market by hyrimoz, rixathon and erelzi Sandoz is becoming a more autonomous and lean division of Novartis In 2020, Novartis expects the innovative drug business to achieve medium to high single digit growth, and Sandoz to achieve low single digit growth Novartis' business in China is expected to double by 2024 GSK's sales volume in 2009 was 33.75 billion pounds ($43.67 billion, + 10%), R & D expenses were 4.57 billion pounds (+ 17%), and sales and management expenses were 11.4 billion pounds (+ 15%) Pharmaceutical business revenue was £ 17.55 billion (+ 2%), of which annual sales of respiratory drugs was £ 3.08 billion (+ 18%), key products were trelegy (£ 520 million, + > 100%) and nucala (£ 770 million, + 36%); annual sales of HIV products were £ 4.85 billion (+ 3%), the growth of Juluca (£ 370 million, + > 100%) and doveto (£ 660 million, listed in the first year) was driven by the growth of trimeq and tivic The decline of ay was partially offset, but the latter two products remained the pillar, with a total annual sales of £ 4.22 billion; the annual sales of older drugs (£ 8.776 billion, - 7%) were affected by patent expiration, of which the revenue of advanir (£ 1.73 billion) decreased by 29% Vaccine revenue was £ 7.16 billion (+ 21%), driven mainly by shingrix (£ 1.8 billion, + > 100%) Consumer healthcare revenues were £ 9 billion (+ 17%), oral care products performed strongly (£ 2.67 billion, + 7%), and skin care products were underperformed (£ 620 million) The negative effects on the overall income include: the continuous price pressure of respiratory products, the significant increase of investment in oncology research and development and promotion product support, the high cost of vaccine inventory and the consumer healthcare product portfolio In 2020, GSK expects earnings per share to fall by - 1% to - 4% in 2020 The company has launched a two-year split plan: "new" GSK is a biopharmaceutical company focusing on scientific research related to immune system, genetics and new technology; and the consumer healthcare business will become an independent company The goal is to improve operational performance and save £ 700m per year by 2022 Sanofi Sanofi's sales volume in 2019 is 36.13 billion euros (about 39.42 billion dollars, + 2.8%), R & D expenditure is 6.02 billion euros (+ 0.2%), and sales and management expenditure is 9.88 billion euros (- 1.4%) The annual revenue of pharmaceutical business is 25.71 billion euros (about 28.05 billion US dollars, + 2.2%), including sanofigenzyme (9.2 billion euros, + 22.4%), primary care business (9.08 billion euros, - 14.8%), China and emerging markets business (7.44 billion euros, + 6.4%) The key products are dupixent (2.07 billion euros, + 151.6%), kevzara (190 million euros, + 114.5%) and multiple sclerosis drug aubagio (1.88 billion euros, + 10%) However, the annual sales of diabetes products Lantus dropped to 3.012 billion euros (- 17.0%), mainly due to the decline of sales in emerging markets Sanofi and mylan will continue to sue and adjudicate Lantus' formula patent rights in 2020 Annual revenue of consumer health business is 4.69 billion euro (- 0.8%)